FDAnews Drug Daily Bulletin

Novartis Study Show Patients Having More Positive Response With Tasigna Compared to Gleevec

Dec. 15, 2011
A A
Phase III clinical trial data presented today contribute to the growing evidence that adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are treated with Tasigna (nilotinib) have deeper levels of response compared to those treated with Gleevec (imatinib mesylate) tablets.
StreetInsider